To identify novel DRG aberrations associated with PARPi sensitivity in CRPC, we performed multiple CRISPR/Cas9 genotoxic screens in BRCA1/2 proficient PCa cell lines treated with the 2 PARPi OLA and talazoparib (TALA) and using a custom sgRNA library targeting 356 DRG belonging to 7 different DNA repair pathways. This evidence concerns the gene BRCA1 and posterior cortical atrophy.